Dapagliflozin/saxagliptin

From Wikipedia, the free encyclopedia

Dapagliflozin/saxagliptin
Combination of
DapagliflozinSGLT-2 inhibitor
SaxagliptinDipeptidyl peptidase-4 inhibitor
Clinical data
Trade namesQtern
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG


Dapagliflozin/saxagliptin, sold under the brand name Qtern, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[2][3] It is a combination of dapagliflozin and saxagliptin.[2][3] It is taken by mouth.[2][3]

The most common side effects include upper respiratory tract infection (such as nose and throat infections) and, when used with a sulphonylurea, hypoglycaemia (low blood glucose levels).[3]

Dapagliflozin/saxagliptin was approved for medical use in the European Union in July 2016, and in the United States in February 2017.[3][4]

Medical uses[edit]

In the United States dapagliflozin/saxagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[2]

In the European Union it is indicated in adults aged 18 years and older with type 2 diabetes mellitus:

  • to improve glycemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycemic control.[3]
  • when already being treated with saxagliptin and dapagliflozin.[3]

References[edit]

  1. ^ a b "Dapagliflozin / saxagliptin (Qtern) Use During Pregnancy". Drugs.com. 28 June 2019. Retrieved 14 July 2020.
  2. ^ a b c d e "Qtern- dapagliflozin and saxagliptin tablet, film coated". DailyMed. 24 January 2020. Retrieved 14 July 2020.
  3. ^ a b c d e f g h "Qtern EPAR". European Medicines Agency (EMA). Retrieved 14 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. ^ "Drug Approval Package: Qtern (dapagliflozin and saxagliptin)". U.S. Food and Drug Administration (FDA). 10 October 2018. Retrieved 14 July 2020.

External links[edit]